A Triazolotriazine‐Based Dual GSK‐3β/CK‐1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition
Stephanie Federico(University of Trieste), Daniel I. Pérez(Cedars-Sinai Medical Center), Paola Storici(Elettra-Sincrotrone Trieste S.C.p.A.), Stefano Moro(University of Padua), Andrea Cavalli(Italian Institute of Technology), Giampiero Spalluto(University of Trieste), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Rita De Zorzi(University of Trieste), Paola Bisignano(Vanderbilt University), Giovanni Bottegoni(University of Urbino), Teresa De Vita(Italian Institute of Technology), Irene Marcovich(University of Trieste), Nicola Demitri(Elettra-Sincrotrone Trieste S.C.p.A.), Maicol Bissaro(University of Padua), Concepción Pérez(Instituto de Química Médica)
Cited by 39
Related Papers
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway
|Journal of Neuroinflammation|2019|518
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334